ClinicalTrials.gg
CompletedNCT00171223Updated Jul 22, 2021Results posted

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

A Phase 2 interventional study of STI571 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-22.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 9 months after the study started (first participant enrolled Dec 1999, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
532
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 1 open to participants now, 5 under way, none of them phase 3. imatinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
5th of 83
532 · median 60
Started
1999
with 2 others
Phase 2
48 of 93
none open now
Registered
29th of 93
by date
Lead sponsor
15 of 93
Novartis Pharmaceuticals

Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 5th largest by enrollment of the 83 interventional ones that give a count, is one of 3 that started in 1999, is one of 48 in phase 2, and was the 29th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

1 of the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase of the study provided that, in the opinion of the investigator, they had benefited from treatment with STI571 and there were no safety concerns.

03

Conditions studied

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Keywords

  • Chronic Myelogenous Leukemia
  • CML
  • Philadelphia Chromosome
  • Accelerated phase
  • Acute Myelogenous Leukemia
  • AML
  • Acute Lymphoblastic Leukemia
  • ALL
  • Imatinib mesylate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants included in the study were:

  • Consenting males or females greater than or equal to (≥)18 years of age with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML).
  • With a documented failure of interferon-alpha (IFN) or an IFN-containing therapy, characterized as resistance or refractoriness defined as any of the following:

    • Hematologic Resistance - Failure to achieve a complete hematological response (CHR), lasting for at least 1 month despite 6 or more months of IFN or an IFN-containing regimen, in which IFN was administered at a dose of at least 25 million international units (MIU) per week. During this treatment period the cumulative duration of hydroxyurea therapy may not have exceeded 50% of the treatment period with the IFN-containing regimen.
    • Cytogenetic Resistance - Bone marrow cytogenetics showing ≥65% Ph+ after one year of IFN-based therapy,
    • Cytogenetic Refractoriness - An increase in the Ph+ chromosome in BM cells by at least 30 percentage points (e.g. from 20% to 50%, or from 30% to 60%) confirmed by two samples at least 1 month apart, or an absolute increase to ≥65%,
    • Hematologic Refractoriness - A rising white blood cell count (WBC) [to a level ≥20 x 10\^9/L confirmed by two samples taken at least two weeks apart] for participants achieving a complete hematologic response while receiving IFN or an IFN-containing regimen. This regimen must have included IFN at a dose of at least 25 MIU administered per week. During this treatment period the cumulative duration of hydroxyurea therapy may not have exceeded 50% of the treatment period with the IFN-containing regimen.

In this report all populations were referred to as "relapsed" populations.

  • With a documented intolerance to IFN therapy defined as a ≥Grade 3 non-hematologic toxicity persisting for at least one month, for participants receiving IFN or an IFN- containing regimen. IFN was to be administered at a dose of at least 25 MIU/week. Participants who were intolerant of IFN were to have been diagnosed ≥6 months prior to the time of entry into the study.

Exclusion criteria

Exclusion Criteria:

Participants excluded from the study were:

  • Females of without a negative pregnancy test prior to the initiation of study drug. Barrier precautions were to be used throughout the trial in both sexes.
  • With serum and creatinine concentrations more than twice the (ULN).
  • With serum glutamic oxaloacetic transaminase () and serum glutamic pyruvic transaminase (SGPT) more than twice the ULN.
  • With >15% of blasts or basophils in peripheral blood (PB) or bone marrow (BM).
  • With ≥30% of blasts plus promyelocytes in PB or BM.
  • With a count of less than (\<)100 x 10\^9/L.
  • With an (ECOG) Performance Status Score ≥3.
  • Receiving busulfan within 6 weeks of Day 1.
  • Receiving treatment with IFN or cytosine arabinoside (Ara-C) within 14 days of Day 1.
  • Receiving treatment with hydroxyurea within 7 days of Day 1.
  • Receiving other agents within 28 days of Day 1.
  • With prior marrow or stem cell transplantation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
532 participants (actual)

Study arms

  • Experimental
    All Participants With Chronic Myeloid Leukemia

    Participants received STI571, capsules or tablets, orally, once a day at a dose of 400 mg. During the Core Phase of the study, participants received STI571 daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase of the study, and they continued STI571 for as long as the therapy was beneficial or until death, intolerable toxicity or the decision to discontinue by the investigator, whichever came first. (Maximum duration on study was approximately 14 years).

    Drug: STI571

Interventions

  • DrugSTI571

    STI571 oral capsules or tablets.

    Also known as: Imatinib Mesylate

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Cytogenetic Response (Complete Cytogenetic Response and Major Cytogenetic Response) to STI571

    Response was evaluated from bone marrow aspirates and biopsy samples. Bone marrow cytogenetic studies were performed every 3 months during the core phase of the study, then twice yearly, then annually to evaluate Philadelphia chromosome positive (Ph+). Cytogenetic response was defined as the best response the participant achieved during study. Based on the percentage of Ph+ cells = (positive cells/ examined cells) x100, at each BM assessment the cytogenetic response was classified as: Complete Cytogenetic Response (CCyR):, 0% Ph+ cells; Partial Cytogenetic Response (PCyR):, \>0 - 35% Ph+ cells; Minor: \>35 - 65% Ph+ cells; and Minimal: \>65 - 95% Ph+ cells, None: \>95 % Ph+ cells and Not done: \<20 metaphases were examined and/or response could not be assigned. Major Cytogenetic Response (MCyR) was defined as sum of the CCyR plus PCyR rates.

    Time frame: Up to 6 years after the start of treatment

Secondary outcomes

  1. Percentage of Participants With Complete Hematologic Response to STI571

    Hematologic response was evaluated from hematology measurements in the peripheral blood. Complete hematological response was defined as normalization of peripheral blood counts \[WBC and platelet count \< upper limit of normal (ULN) at the laboratory where the analysis was performed\], with a normal WBC differential, and no immature granulocytes present, lasting for 4 weeks.

    Time frame: 12 months after the start of treatment

  2. Duration of Complete Hematologic Response to STI571

    Duration of hematologic response was defined as the time from the first documentation of the complete hematologic response to the date the loss of complete hematologic response is documented. Loss of complete hematological response was defined as a rising WBC count (increased to a level above the ULN at the laboratory where the analysis was performed confirmed by two samples obtained one month apart). The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time. Complete hematological response was defined as normalization of peripheral blood counts (WBC and platelet count \< ULN at the laboratory where the analysis was performed), with a normal WBC differential, and no immature granulocytes present, lasting for 4 weeks.

    Time frame: 12 months after the start of treatment

  3. Time to Complete Hematologic Response to STI571

    Time to Complete Hematologic Response was defined for all participants with calculated confirmed complete hematologic response as the time until first documented response (which was confirmed \>= 4 weeks). Complete hematological response was defined as normalization of peripheral blood counts (WBC and platelet count \< ULN at the laboratory where the analysis was performed), with a normal WBC differential, and no immature granulocytes present, lasting for 4 weeks.

    Time frame: 12 months after the start of treatment

  4. Number of Participants With Common Toxicity Criteria Grade 3 or 4 Cancer-related Symptoms

    National Cancer Institute (NCI)/ National Institute of Health (NIH) provides a grading (severity) scale for each adverse event (AE) term, the Common Toxicity Criteria (CTC). Grade 3 refers to severe AE and Grade 4 refers to life-threatening or disabling AE. Cancer-related symptoms included fever, night sweats, bone pain, arthralgia, abdominal discomfort, fatigue and anorexia.

    Time frame: Up to 9 months after the start of treatment

  5. Number of Participants With Grade 3 or 4 Eastern Cooperative Oncology Group (ECOG) Performance Status

    The ECOG performance status was recorded at baseline and every 3 months during the core study. The ECOG Performance Scale has 5 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair.

    Time frame: Up to 9 months after the start of treatment

  6. Percentage of Participants Alive Over Time Based on Kaplan-Meier Estimates

    Overall survival was defined as the time from the first dose of STI571 to the death of the participant. If a participant is not known to have died, survival was censored at the time of last contact. Kaplan-Meier estimates of the percentage of participants at each time point was calculated.

    Time frame: 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 and 156 months

07

Results

Posted Jul 22, 2021

Participant flow

Participant flow — Overall Study
MilestoneHematologic FailureCytogenetic FailureInterferon-alpha Intolerance
Started152188192
Completed124722
Not completed140141170
Withdrew: Adverse event (non-fatal)6519
Withdrew: Abnormal laboratory value (s)423
Withdrew: Abnormal procedure100
Withdrew: Unsatisfactory therapeutic effect574352
Withdrew: No longer requires study drug (bone marrow transplant)242
Withdrew: Protocol violation223
Withdrew: Participant withdrew consent122115
Withdrew: Lost to follow-up523
Withdrew: Administrative problems476
Withdrew: Adverse event (serious fatal)689
Withdrew: Not specified (no data collected after cut-off)414758

Outcome measures

PrimaryPercentage of Participants With Cytogenetic Response (Complete Cytogenetic Response and Major Cytogenetic Response) to STI571

Response was evaluated from bone marrow aspirates and biopsy samples. Bone marrow cytogenetic studies were performed every 3 months during the core phase of the study, then twice yearly, then annually to evaluate Philadelphia chromosome positive (Ph+). Cytogenetic response was defined as the best response the participant achieved during study. Based on the percentage of Ph+ cells = (positive cells/ examined cells) x100, at each BM assessment the cytogenetic response was classified as: Complete Cytogenetic Response (CCyR):, 0% Ph+ cells; Partial Cytogenetic Response (PCyR):, \>0 - 35% Ph+ cells; Minor: \>35 - 65% Ph+ cells; and Minimal: \>65 - 95% Ph+ cells, None: \>95 % Ph+ cells and Not done: \<20 metaphases were examined and/or response could not be assigned. Major Cytogenetic Response (MCyR) was defined as sum of the CCyR plus PCyR rates.

Time frame:
Up to 6 years after the start of treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Cytogenetic Response (Complete Cytogenetic Response and Major Cytogenetic Response) to STI571
percentage of participantsHematologic FailureCytogenetic FailureInterferon-alpha Intolerance
Complete Cytogenetic Response29.6 (22.5 to 37.5)37.2 (30.3 to 44.6)45.8 (38.6 to 53.2)
Major Cytogenetic Response45.4 (37.3 to 53.7)63.8 (56.5 to 70.7)65.6 (58.4 to 72.3)
SecondaryPercentage of Participants With Complete Hematologic Response to STI571

Hematologic response was evaluated from hematology measurements in the peripheral blood. Complete hematological response was defined as normalization of peripheral blood counts \[WBC and platelet count \< upper limit of normal (ULN) at the laboratory where the analysis was performed\], with a normal WBC differential, and no immature granulocytes present, lasting for 4 weeks.

Time frame:
12 months after the start of treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Hematologic Response to STI571
percentage of participantsHematologic FailureCytogenetic FailureInterferon-alpha Intolerance
Percentage of Participants With Complete Hematologic Response to STI57194.1 (89.1 to 97.3)97.9 (94.6 to 99.4)91.7 (86.8 to 95.2)
SecondaryDuration of Complete Hematologic Response to STI571

Duration of hematologic response was defined as the time from the first documentation of the complete hematologic response to the date the loss of complete hematologic response is documented. Loss of complete hematological response was defined as a rising WBC count (increased to a level above the ULN at the laboratory where the analysis was performed confirmed by two samples obtained one month apart). The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time. Complete hematological response was defined as normalization of peripheral blood counts (WBC and platelet count \< ULN at the laboratory where the analysis was performed), with a normal WBC differential, and no immature granulocytes present, lasting for 4 weeks.

Time frame:
12 months after the start of treatment
Reported as:
Mean · months
Duration of Complete Hematologic Response to STI571
monthsHematologic FailureCytogenetic FailureInterferon-alpha Intolerance
Duration of Complete Hematologic Response to STI57119.3672 ± 0.638323.9389 ± 0.50624.6818 ± 0.6507
SecondaryTime to Complete Hematologic Response to STI571

Time to Complete Hematologic Response was defined for all participants with calculated confirmed complete hematologic response as the time until first documented response (which was confirmed \>= 4 weeks). Complete hematological response was defined as normalization of peripheral blood counts (WBC and platelet count \< ULN at the laboratory where the analysis was performed), with a normal WBC differential, and no immature granulocytes present, lasting for 4 weeks.

Time frame:
12 months after the start of treatment
Reported as:
Median · months
Time to Complete Hematologic Response to STI571
monthsHematologic FailureCytogenetic FailureInterferon-alpha Intolerance
Time to Complete Hematologic Response to STI5711.64 (0.6 to 2.8)0.72 (0.3 to 2.8)0.72 (0.3 to 2.8)
SecondaryNumber of Participants With Common Toxicity Criteria Grade 3 or 4 Cancer-related Symptoms

National Cancer Institute (NCI)/ National Institute of Health (NIH) provides a grading (severity) scale for each adverse event (AE) term, the Common Toxicity Criteria (CTC). Grade 3 refers to severe AE and Grade 4 refers to life-threatening or disabling AE. Cancer-related symptoms included fever, night sweats, bone pain, arthralgia, abdominal discomfort, fatigue and anorexia.

Time frame:
Up to 9 months after the start of treatment
Reported as:
Count of participants · Participants
Number of Participants With Common Toxicity Criteria Grade 3 or 4 Cancer-related Symptoms
ParticipantsHematologic FailureCytogenetic FailureInterferon-alpha Intolerance
Abdominal Discomfort Grade 3000
Abdominal Discomfort Grade 4000
Anorexia Grade 3000
Anorexia Grade 4000
Arthralgia Grade 3001
Arthralgia Grade 4000
Bone Pain Grade 3010
Bone Pain Grade 4000
Fatigue Grade 3100
Fatigue Grade 4000
Fever Grade 3000
Fever Grade 4000
Night Sweats Grade 3000
Night Sweats Grade 4000
SecondaryNumber of Participants With Grade 3 or 4 Eastern Cooperative Oncology Group (ECOG) Performance Status

The ECOG performance status was recorded at baseline and every 3 months during the core study. The ECOG Performance Scale has 5 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair.

Time frame:
Up to 9 months after the start of treatment
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or 4 Eastern Cooperative Oncology Group (ECOG) Performance Status
ParticipantsHematologic FailureCytogenetic FailureInterferon-alpha Intolerance
Grade 3100
Grade 4000
SecondaryPercentage of Participants Alive Over Time Based on Kaplan-Meier Estimates

Overall survival was defined as the time from the first dose of STI571 to the death of the participant. If a participant is not known to have died, survival was censored at the time of last contact. Kaplan-Meier estimates of the percentage of participants at each time point was calculated.

Time frame:
12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 and 156 months
Reported as:
Number · percentage of participants
Percentage of Participants Alive Over Time Based on Kaplan-Meier Estimates
percentage of participantsHematologic FailureCytogenetic FailureInterferon-alpha Intolerance
12 Months94.7 (89.8 to 97.3)98.9 (95.8 to 99.7)97.4 (93.9 to 98.9)
24 Months88.1 (81.8 to 92.3)93.6 (89 to 96.3)89.5 (84.3 to 93.1)
36 Months84 (77.1 to 89)91.5 (86.5 to 94.7)83.8 (77.7 to 88.3)
48 Months78.4 (70.9 to 84.2)87.1 (81.4 to 91.2)76.3 (69.6 to 81.7)
60 Months73.3 (65.2 to 79.7)83.8 (77.6 to 88.4)73.6 (66.7 to 79.3)
72 Months70.1 (61.9 to 76.9)79.7 (73.1 to 84.9)71.4 (64.3 to 77.3)
84 Months68.5 (60 to 75.5)79.7 (73.1 to 84.9)67.2 (59.9 to 73.5)
96 Months66.5 (57.9 to 73.8)79.1 (72.3 to 84.3)65.9 (58.6 to 72.3)
108 Months63.3 (54.3 to 71)78.4 (71.6 to 83.7)65.3 (57.9 to 71.7)
120 Months61 (51.8 to 69)77 (70 to 82.5)63.8 (56.3 to 70.4)
132 Months59.7 (50.4 to 67.9)75.4 (68.2 to 81.2)62.3 (54.6 to 69)
144 Months57 (47.2 to 65.5)73.8 (66.4 to 79.8)60.8 (53 to 67.6)
156 Months55.5 (45.6 to 64.3)70.1 (62.1 to 76.7)60.8 (53 to 67.6)

Adverse events

Collected over Up to approximately 14 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants With Chronic Myeloid Leukemia—13/532 (2.4%)—
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventAll Participants With Chronic Myeloid Leukemia
Hip fractureInjury, poisoning and procedural complications1/532
FallInjury, poisoning and procedural complications1/532
Head injuryInjury, poisoning and procedural complications1/532
SarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/532
Prostate AdenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/532
Atrial fibrillationCardiac disorders1/532
Febrile neutropeniaBlood and lymphatic system disorders1/532
PneumoniaRespiratory, thoracic and mediastinal disorders1/532
AsthmaRespiratory, thoracic and mediastinal disorders1/532
Generalised oedemaGeneral disorders1/532

Baseline characteristics

Intent-to-treat (ITT) population included all enrolled participants.

Age, Continuous
Age, Continuous(years)Hematologic FailureCytogenetic FailureInterferon-alpha IntoleranceTotal
Median55.5 (18 to 79)53.0 (23 to 77)59.0 (20 to 90)57.0 (18 to 90)
Age, Customized
Age, Customized(Participants)Hematologic FailureCytogenetic FailureInterferon-alpha IntoleranceTotal
Less than (<) 50 years576447168
>= 50 to <= 60 years386550153
>= 60 to <= 70 years474468159
>= 70 years10152752
Sex: Female, Male
Sex: Female, Male(Participants)Hematologic FailureCytogenetic FailureInterferon-alpha IntoleranceTotal
Female507794221
Male10211198311
08

Study locations

28 sites
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • H. Lee Moffet Cancer Center & Research Institute/Univ of South Florida
    Tampa, Florida 33612, United States
  • Northwestern Univ meical School/Robert H. Lurie Comprehensive Cancer Center
    Chicago, Illinois 60611, United States
  • Johns Hopkins Oncology Center
    Baltimore, Maryland 21231, United States
  • Dana Faber Cancer Institute
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Wayne State University/Kamanos Cancer Center
    Detroit, Michigan 48201, United States
  • C/O V. Ward - Washington Univ. school of Medicine
    Saint Louis, Missouri 63110, United States
  • New York Presbyterian Hospital
    New York, New York 10021, United States
  • Oregon Health & sciences University
    Portland, Oregon 97239, United States
  • MD Anderson Cancer Center, University of Texas
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Lille, France
  • Novartis Investigative Site
    Pessac, France
  • Novartis Investigative Site
    Poitiers, France
  • Novartis Investigative Site
    Frankfurt, Germany
  • Novartis Investigative Site
    Leipzig, Germany
  • Novartis Investigative Site
    Mainz, Germany
  • Novartis Investigative Site
    Mannheim, Germany
  • Novartis Investigative Site
    Bologna, Italy
  • Novartis Investigative Site
    Milano, Italy
  • Novartis Investigative Site
    Monza, Italy
  • Novartis Investigative Site
    Orbassano, Italy
  • Novartis Investigative Site
    Pavia, Italy
  • Novartis Investigative Site
    Rome, Italy
  • Novartis Investigative Site
    Udine, Italy
  • Novartis Investigative Site
    Basel, Switzerland
  • Novartis Investigative Site
    London, United Kingdom
  • Novartis Investigative Site
    Newcastle upon Tyne, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 1999 to primary completion in Nov 2013, 167 months.

Results were first posted in Jul 2021, 7 years 7 months after primary completion.

Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 167 months is above that.

Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 15, 2005
StartActual
Dec 6, 1999
Primary completionActual
Nov 29, 2013
CompletionActual
Nov 29, 2013
Results first posted
Jul 22, 2021
Last update
Jul 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00171223
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Dec 6, 1999
Primary completion
Nov 29, 2013
Completion
Nov 29, 2013
Results posted
Jul 22, 2021
Last update
Jul 22, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion